NeoFlow

Company Overview

Snapshot

Founded in January 2023 by David Skorohod, Maroun Farah, and Limor Sandach, NeoFlow operates with 1–10 employees. The company has secured funding across one round from one investor, NGT HealthCare II.

Business overview

NeoFlow develops novel endovascular solutions specifically for treating vasospasm in Aneurysmal Subarachnoid Hemorrhage (aSAH). The company's core technology aims to provide a widely accessible, simple-design endovascular device that achieves vasoconstriction relief through local manipulation, thereby reducing the risks associated with traditional balloon angioplasty and systemic pharmacological treatments. NeoFlow operates within the Health Tech & Life Sciences sector, focusing on medical devices and medical treatment & therapeutics, primarily serving healthcare providers.

Company Intelligence Q&A

What is NeoFlow's primary focus?

NeoFlow is focused on developing novel endovascular solutions for the treatment of vasospasm in Aneurysmal Subarachnoid Hemorrhage (aSAH).

When was NeoFlow founded and by whom?

NeoFlow was founded in January 2023 by David Skorohod, Maroun Farah, and Limor Sandach.

Which investor participated in NeoFlow's funding round?

NGT HealthCare II participated in NeoFlow's Pre-Seed funding round in January 2023.

What is the current status of NeoFlow?

NeoFlow is currently non-active and ceased to operate in September 2025.

What is the product stage of NeoFlow's technology?

NeoFlow's product is currently in the R&D stage, focusing on developing a widely accessible, simple-design endovascular device for vasoconstriction relief.